Overview
- Anvisa approved five GLP‑1 injectable pens on October 29, 2026, bringing the agency’s total approvals for the class this year to 20.
- The new approvals are Aribet, Lyrza and Wylovol (liraglutide) and Embeltah and Sevema (semaglutide), with registrations listing Farma Vision/Biocon, Dr. Reddy’s/OneSource Specialty and Aché/OneSource Specialty as registrants and manufacturers.
- Approval expands the pool of authorized products but does not guarantee immediate pharmacy availability or lower consumer prices because manufacturers must still set launch plans and CMED controls price ceilings.
- Brazil requires retained medical prescriptions for GLP‑1 sales since 2025 and Anvisa stresses that identical active ingredients can have different indications and dosing, so a diabetes approval does not automatically cover obesity treatment.
- GLP‑1 agonists mimic an intestinal hormone to lower blood sugar and reduce appetite, they differ in dosing frequency, and they can cause nausea and rarer serious harms such as acute pancreatitis, so clinical evaluation is required before use.